Follow
Prof Shira Zelber-Sagi
Prof Shira Zelber-Sagi
The University of Haifa
Verified email at bezeqint.net
Title
Cited by
Cited by
Year
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ...
Journal of hepatology 73 (1), 202-209, 2020
29022020
Treatment of NAFLD with diet, physical activity and exercise
M Romero-Gómez, S Zelber-Sagi, M Trenell
Journal of hepatology 67 (4), 829-846, 2017
11532017
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
SG Sepanlou, S Safiri, C Bisignano, KS Ikuta, S Merat, M Saberifiroozi, ...
The Lancet gastroenterology & hepatology 5 (3), 245-266, 2020
11492020
EASL Clinical Practice Guidelines on nutrition in chronic liver disease
M Merli, A Berzigotti, S Zelber-Sagi, S Dasarathy, S Montagnese, ...
Journal of hepatology 70 (1), 172-193, 2019
7852019
Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study
S Zelber-Sagi, D Nitzan-Kaluski, R Goldsmith, M Webb, L Blendis, ...
Journal of hepatology 47 (5), 711-717, 2007
6512007
Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence
S Zelber-Sagi, V Ratziu, R Oren
World journal of gastroenterology: WJG 17 (29), 3377, 2011
553*2011
A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
S Zelber–Sagi, A Kessler, E Brazowsky, M Webb, Y Lurie, M Santo, ...
Clinical Gastroenterology and Hepatology 4 (5), 639-644, 2006
4262006
Advancing the global public health agenda for NAFLD: a consensus statement
JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ...
Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022
4132022
Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures
S Zelber‐Sagi, D Nitzan‐Kaluski, Z Halpern, R Oren
Liver International 26 (7), 856-863, 2006
3782006
Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis
M Webb, H Yeshua, S Zelber-Sagi, E Santo, E Brazowski, Z Halpern, ...
American Journal of Roentgenology 192 (4), 909-914, 2009
3682009
Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up
S Zelber-Sagi, R Lotan, A Shlomai, M Webb, G Harrari, A Buch, ...
Journal of hepatology 56 (5), 1145-1151, 2012
3312012
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study
S Zelber-Sagi, D Nitzan-Kaluski, R Goldsmith, M Webb, I Zvibel, I Goldiner, ...
Hepatology 48 (6), 1791-1798, 2008
3282008
The fatty acid–bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease
R Safadi, FM Konikoff, M Mahamid, S Zelber-Sagi, M Halpern, T Gilat, ...
Clinical Gastroenterology and Hepatology 12 (12), 2085-2091. e1, 2014
3142014
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri, G Dusheiko, E Bugianesi, ...
The Lancet 399 (10319), 61-116, 2022
3132022
Natural antioxidants for non‐alcoholic fatty liver disease: molecular targets and clinical perspectives
F Salomone, J Godos, S Zelber‐Sagi
Liver International 36 (1), 5-20, 2016
2632016
The Mediterranean dietary pattern as the diet of choice for non‐alcoholic fatty liver disease: evidence and plausible mechanisms
S Zelber‐Sagi, F Salomone, L Mlynarsky
Liver International 37 (7), 936-949, 2017
2582017
High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance
S Zelber-Sagi, D Ivancovsky-Wajcman, NF Isakov, M Webb, D Orenstein, ...
Journal of hepatology 68 (6), 1239-1246, 2018
2462018
Re‐evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large‐scale population study
R Kariv, M Leshno, A Beth‐Or, H Strul, L Blendis, E Kokia, D Noff, ...
Liver international 26 (4), 445-450, 2006
1752006
Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial
S Zelber-Sagi, A Buch, H Yeshua, N Vaisman, M Webb, G Harari, O Kis, ...
World journal of gastroenterology: WJG 20 (15), 4382, 2014
1662014
Non-alcoholic fatty liver disease: A patient guideline
SM Francque, G Marchesini, A Kautz, M Walmsley, R Dorner, JV Lazarus, ...
JHEP reports 3 (5), 100322, 2021
1592021
The system can't perform the operation now. Try again later.
Articles 1–20